

**PROSPECTUS SUPPLEMENT NO. 12 DATED FEBRUARY 17, 2015  
TO  
PROSPECTUS DATED JULY 2, 2014  
(AS SUPPLEMENTED)**

**ARCH THERAPEUTICS, INC.**

**PROSPECTUS**

**Up to 45,600,000 Shares of Common Stock**

This Prospectus Supplement No. 12 supplements the prospectus of Arch Therapeutics, Inc. (“the “Company”, “we”, “us”, or “our”) dated July 2, 2014 (as supplemented to date, the “Prospectus”) with the following attached document which we filed with the Securities and Exchange Commission on February 17, 2015:

- A. Our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 17, 2015

This Prospectus Supplement No. 12 should be read in conjunction with the Prospectus, which is required to be delivered with this Prospectus Supplement. This prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

**Investing in our common stock involves a high degree of risk. Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are described in the Prospectus, as amended or supplemented.**

**You should rely only on the information contained in the Prospectus, as supplemented or amended by this Prospectus Supplement No. 12 and any other prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this Prospectus Supplement No. 12 is February 17, 2015

---

**INDEX TO FILINGS**

The Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 17, 2015 

---

**Annex**  
A

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 17, 2015**

**ARCH THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-54986**  
(Commission  
File Number)

**46-0524102**  
(I.R.S. Employer  
Identification No.)

**20 William Street, Suite 270**  
**Wellesley, Massachusetts**  
(Address of principal executive offices)

**02481**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 431-2313**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On February 17, 2015, Arch Therapeutics, Inc. (the “Company”) issued a press release announcing confirmation from The British Standards Institution (BSI) that its AC5™ product fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibit**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release issued by Arch Therapeutics, Inc. on February 17, 2015

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCH THERAPEUTICS, INC.**

Dated: February 17, 2015

By: /s/ Terrence W. Norchi, M.D.  
Name: Terrence W. Norchi, M.D.  
Title: President, Chief Executive Officer

---

EXHIBIT INDEX

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release issued by Arch Therapeutics, Inc. on February 17, 2015

---

## The British Standards Institution Classifies Arch Therapeutics' AC5™ as a Medical Device Within the European Union

### *AC5 Surgical Hemostatic Device™ Fulfills Definition of a Medical Device CE Mark Designation*

**WELLESLEY, MA – February 17, 2015** -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a medical device company and developer of the AC5 Surgical Hemostatic Device™ (AC5™), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU.

BSI reviewed the scientific information provided by Arch detailing that the mechanism of hemostasis activity of AC5 results from the self-assembly of the product into a mechanical barrier, which seals the tissue to stop bleeding. BSI has concluded that the primary mode of action is physical and fulfills the definition of a medical device. BSI has further concluded that AC5 was without ancillary medicinal activity.

A Notified Body such as BSI is an organization that has been accredited by a member state of the EU to determine whether a product meets certain preordained standards to receive a CE mark designation. Arch intends to enter the hemostasis and sealant market in Europe.

Terrence Norchi, MD, President and CEO of Arch Therapeutics, stated, "This notification from BSI is an important milestone for the Company. It confirms what we have long believed about AC5's properties, specifically with regard to its underlying barrier mechanism of action, which we believe differentiates AC5 from currently available products. I am pleased that we have received this ruling, which removes a significant risk and potential burden from our commercialization strategy."

#### **About BSI**

BSI's mission is to ensure patient safety while supporting timely access to global medical device technology. They provide thorough, responsive, predictable conformity assessments, evaluations and certifications that are recognized and accepted worldwide. To learn more, visit [medicaldevices.bsigroup.com](http://medicaldevices.bsigroup.com)

#### **About Arch Therapeutics, Inc.**

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Find out more at [www.archtherapeutics.com](http://www.archtherapeutics.com).

---

**Notice Regarding Forward-Looking Statements**

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at [www.sec.gov](http://www.sec.gov).

On Behalf of the Board,  
Terrence W. Norchi, MD  
Arch Therapeutics, Inc.

**Contact:**

ARTH Investor Relations  
Toll Free: +1-855-340-ARTH (2784) (US and Canada)  
Email: [investors@archtherapeutics.com](mailto:investors@archtherapeutics.com)  
Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

Or

Richard Davis  
Chief Financial Officer  
Arch Therapeutics, Inc.  
Phone: 617-431-2308  
Email: [rdavis@archtherapeutics.com](mailto:rdavis@archtherapeutics.com)  
Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

---